ArticleEuropean radiology2022
Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
Open access · greenAbstract read
In one paragraph
Article in European radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 21 citations in OpenAlex.
- Bioengineered systems to exploit tumor microenvironment metabolism.Trends in cancer · 2026Review
- Clinical outcomes and prognostic factors of systemic therapy combined with interventional treatment in hepatocellular carcinoma: a multicenter retrospective case series.Translational cancer research · 2026Article
- SIRT or TACE in combination with Lenvatinib and PD-(L)1 inhibitor in high tumor burden hepatocellular carcinoma: a multicenter, retrospective, propensity score-matched study.International journal of surgery (London, England) · 2025Article
- Targeting lactic acidosis in the tumor microenvironment: Enhancing TACE efficacy in hepatocellular carcinoma.Liver research (Beijing, China) · 2025Review
- Immunologic effects of locoregional therapies for unresectable hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2025Article
- TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study.Journal of hepatocellular carcinoma · 2025Article
- Drug-eluting beads chemoembolization combined with programmed cell death 1 inhibitor and lenvatinib for large hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024Article
- Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.Cancer immunology, immunotherapy : CII · 2024Article
- Relaxin combined with transarterial chemoembolization achieved synergistic effects and inhibited liver cancer metastasis in a rabbit VX2 model.Journal of cancer research and clinical oncology · 2024Article
- Transmembrane pH gradient imaging in rodent glioma models.NMR in biomedicine · 2024Article
- Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review.Frontiers in immunology · 2024Review
- The Role of Lactate Dehydrogenase in Exploring the Immune Evasion in HCC Patients Who Underwent TACE: Implications for Clinical Application.Journal of hepatocellular carcinoma · 2024Article
- Intermediate-stage (BCLC stage B) infiltrative hepatocellular carcinoma: safety and efficacy of chemoembolization.European radiology · 2023Article
- Precise localization of microvascular invasion in hepatocellular carcinoma based on three-dimensional histology-MR image fusion: anQuantitative imaging in medicine and surgery · 2023Article
- Article
- Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study.Frontiers in immunology · 2023Article
- Article
- Role of interventional oncology in hepatocellular carcinoma: Future best practice beyond current guidelines.The British journal of radiology · 2022Review
- Impact of Chemoembolic Regimen on Immune Cell Recruitment and Immune Checkpoint Marker Expression following Transcatheter Arterial Chemoembolization in a VX2 Rabbit Liver Tumor Model.Journal of vascular and interventional radiology : JVIR · 2022Article
- Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Camrelizumab Compared With Conventional Transarterial Chemoembolization Plus Camrelizumab for Unresectable Hepatocellular Carcinoma.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Luzie A DoemelDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Jessica G SantanaDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Lynn J SavicDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Fabian M Laage GauppDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Tabea BordeDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Alexandra Petukhova-GreensteinDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Ahmet S KucukkayaDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Isabel T SchobertDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Charlie A HammDepartment of Diagnostic and Interventional Radiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, 10117, Berlin, Germany.
Bernhard GebauerDepartment of Diagnostic and Interventional Radiology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität, and Berlin Institute of Health, 10117, Berlin, Germany.
John J WalshDepartment of Biomedical Engineering, School of Engineering & Applied Science, 17 Hillhouse Avenue, New Haven, CT, 06510, USA.
Irvin RexhaDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Fahmeed HyderDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
MingDe LinDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
David C MadoffDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Todd SchlachterDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Julius ChapiroDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA. j.chapiro@googlemail.com.ORCID http://orcid.org/0000-0002-1984-2246
Daniel ComanDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, 333 Cedar Street, New Haven, CT, 06510, USA.
Yale University · USYale Cancer Center · USHumboldt-Universität zu Berlin · DETUM Klinikum · DEUniversitätsmedizin Greifswald · DEUniversity of New Haven · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007205 · NIGMS · YALE UNIVERSITY · PI KAZMIERCZAK, BARBARA I · 1985 to 2019
$42.9MYale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1MQuantitative Multimodal Imaging Biomarkers for Combined Locoregional and Immunotherapy of Liver CancerR01CA206180 · NCI · YALE UNIVERSITY · PI CHAPIRO, JULIUS, DUNCAN, JAMES S · 2016 to 2025
$6.1MExtracellular pH mapping as therapeutic readout of drug delivery in glioblastomaR01EB023366 · NIBIB · YALE UNIVERSITY · PI HYDER, DEWAN SYED FAHMEED · 2017 to 2020
$2.5MNCATS NIH HHS UL1 TR001863NCI NIH HHS R01 CA206180NIBIB NIH HHS R01 EB023366NIDDK NIH HHS P30 DK034989NIGMS NIH HHS T32 GM007205NIH HHS R01 CA206180NIH HHS R01 EB023366
Abstract
objectivesThe goal of this study was to investigate the effects of TACE using Lipiodol, Oncozene™ drug-eluting embolics (DEEs), or LUMI™-DEEs alone, or combined with bicarbonate on the metabolic and immunological tumor microenvironment in a rabbit VX2 tumor model.
methodsVX2 liver tumor-bearing rabbits were assigned to five groups. MRI and extracellular pH (pH
resultspH
conclusionsThe choice of chemoembolic regimen for TACE strongly affects post-treatment TME pH KEY POINTS: • Combining conventional transarterial chemotherapy with prior bicarbonate infusion increases the pH
Indexed as
Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsAnimalsDoxorubicinEthiodized OilRabbitsTumor MicroenvironmentDoxorubicinEthiodized OilCarcinoma, hepatocellularChemoembolization, therapeuticImmunohistochemistryRabbitsTumor microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.